We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients (QSYQT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01802021
Recruitment Status : Unknown
Verified April 2009 by Chang Gung Memorial Hospital.
Recruitment status was:  Recruiting
First Posted : March 1, 2013
Last Update Posted : March 1, 2013
Sponsor:
Information provided by (Responsible Party):
Chang Gung Memorial Hospital

Brief Summary:

The myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis, and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other immune suppressive mechanism. The functions of NK cells and regulatory T cells are altered, resulting in a disturbance of anti-tumor immune function. All these can further create an environment with a benefit for malignant cell growth and advancement. Astragalus-based formula may confer its survival advantage in cancer patients through modulating the immune system and reversing the immunosuppressive microenvironment.

The investigators aim to study the role of Qingshu-Yiqi-Tang in reversing the immune alterations in patients with advanced stage, non-small cell lung cancer who receive 1st line doublet chemotherapy of cisplatin plus doxetaxel(or Pemetrexed for adenocarcinoma)and 2nd line target therapy of erlotinib. The investigators can explore the possible mechanism of the Astragalus-based formula: Qingshu-Yiqi-Tang in modulating and reversing immunosuppression in advanced stage, non-small cell lung cancer patients.


Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang Phase 2 Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy
Study Start Date : May 2009
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Qingshu-Yiqi-Tang+standard therapy

Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.

1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.

Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang

Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.

maximal for 6 months

Other Names:
  • Chuang Song Zong Pharmaceutical Co., Ltd. Taiwan.
  • CHING SHUU YIH CHIH TANG /QING SHU YI QI TANG
No Intervention: 1st line doublet chemotherapy
1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.



Primary Outcome Measures :
  1. overall survival [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Progression-free interval [ Time Frame: 3 years ]

Other Outcome Measures:
  1. Quality of Life [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with pathological diagnosis of primary non-small-cell lung cancer Stage IIIB, IV
  2. Age ≧ 18 years
  3. Written, informed consent
  4. ECOG: 0-1

Exclusion Criteria:

  1. Subjects with inflammatory, infectious or immune disorder, such as TB, AIDS, active pneumonia, DM, SLE, rheumatoid disease.
  2. Subjects with systemic organ disease, such as CHF, ESRD, hepatitis, liver cirrhosis.
  3. Subjects with malignancy other than NSCLC.
  4. Subjects receiving anti-inflammatory or immunosuppressor medications, such as steroid (oral, except for chemotherapy premedication, or inhaled), NSAIDs.
  5. Patients with no willing to sign the informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01802021


Locations
Taiwan
Center for traditional chinese medicine, Chang Gung Memorial Hospital Recruiting
Gueishan Township, Taoyuan County, Taiwan, 33378
Contact: Tse-Hung Huang, M.D.    +886-3196200 ext 2613    tsehunghuang_1089@yahoo.com.tw   
Principal Investigator: Tse-Hung Huang, M.D.         
Sponsors and Collaborators
Chang Gung Memorial Hospital
Investigators
Principal Investigator: Tse-Hung Huang, M.D. Chang Gung Memorial Hospital

Responsible Party: Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT01802021     History of Changes
Other Study ID Numbers: 97-1967A3
First Posted: March 1, 2013    Key Record Dates
Last Update Posted: March 1, 2013
Last Verified: April 2009

Keywords provided by Chang Gung Memorial Hospital:
chinese medicine
non-small cell lung cancer
immunosuppression

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms